{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Percentage of participants who achieve or maintain any best response category during the treatment period were reported. Best response includes complete response (CR), very good partial response (VGPR), and partial response (PR). Response was assessed according to IMWG criteria. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hour.","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)","id":"OG000","title":"Ixazomib+Lenalidomide+Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Safety population was defined as all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From Cycle 1, Day 1 to Cycle 3, Day 1 until disease progression (approximately 20 months)","title":"Percentage of Participants With Confirmed Best Response Category","type":"SECONDARY","unitOfMeasure":"percentage of participants"}